

Cite this: *Nanoscale Adv.*, 2023, 5, 5256Received 24th April 2023
Accepted 16th August 2023

DOI: 10.1039/d3na00272a

rsc.li/nanoscale-advances

Synthesis and application of spermine-based amphiphilic poly(β -amino ester)s for siRNA delivery†

Yao Jin,^a Friederike Adams,[‡] Anny Nguyen,^a Sebastian Sturm,^b Simone Carnerio,^a Knut Müller-Caspary^b and Olivia M. Merkel^{‡*}

Small interfering RNA (siRNA) can trigger RNA interference (RNAi) to therapeutically silence disease-related genes in human cells. The approval of siRNA therapeutics by the FDA in recent years generated a new hope in novel and efficient siRNA therapeutics. However, their therapeutic application is still limited by the lack of safe and efficient transfection vehicles. In this study, we successfully synthesized a novel amphiphilic poly(β -amino ester) based on the polyamine spermine, hydrophobic decylamine and 1,4-butanediol diacrylate, which was characterized by ¹H NMR spectroscopy and size exclusion chromatography (SEC, M_n = 6000 Da). The polymer encapsulated siRNA quantitatively from N/P 5 on as assessed by fluorescence intercalation while maintaining optimal polyplex sizes and zeta potentials. Biocompatibility and cellular delivery efficacy were also higher than those of the commonly used cationic, hyperbranched polymer polyethylenimine (PEI, 25 kDa). Optimized formulations mediated around 90% gene silencing in enhanced green fluorescence protein expressing H1299 cells (H1299-eGFP) as determined by flow cytometry. These results suggest that spermine-based, amphiphilic poly(β -amino ester)s are very promising candidates for efficient siRNA delivery.

Introduction

Small interfering RNA (siRNA) is a double-stranded macromolecule with a length of 19–21 nucleotides per strand used to trigger the innate RNA interference (RNAi) mechanism to

degrade complementary mRNA molecules for a subsequent decrease in gene expression.¹ RNAi therapy has preclinically been demonstrated promising for the treatment for many diseases, for example, chronic myeloid leukemia,¹ non-small cell lung cancer,² skin melanoma,³ and many others. It also has the potential to treat COVID-19 caused by SARS-CoV-2 virus infections.^{4,5} Additionally, several siRNA-based products are already approved by the FDA, and many additional siRNA-drugs are in different stages of clinical trials.⁶ However, the physicochemical properties of siRNAs including their macromolecular characteristics, hydrophilicity, net negative charge, enzymatic degradation by serum endonucleases such as RNases, and rapid renal clearance of siRNA require the combination of bioactive sequences with effective delivery systems.^{7,8}

Cationic polymers have shown promise for nucleic acid delivery given their ability to self-assemble with anionic siRNA into condensed nanoparticles (polyplexes) with efficient encapsulation capacity. Various cationic polymers have been developed as nonviral nucleic acid vectors during the past three decades, including polyethylenimine (PEI), chitosan, inulin, poly-L-lysine, and many more.⁹ Poly(β -amino ester)s (PBAEs) are polymers synthesized from acrylate compounds and amine-containing monomers by Michael addition-based step growth polymerization and have drawn people's attention after their first application for transfection in 2000 due to their inherent biocompatibility, biodegradability, and stimuli-responsiveness.^{10,11} The first generation of PBAEs contains linear PBAEs (LPAs), and a variety of LPAs has been established and proven to be promising for gene delivery. However, the delivery of siRNA bears new challenges in comparison to plasmid DNA because siRNA is linear and short with a rigid structure, which affords limited molecular entanglement points to electrostatically bind to cationic polymers.¹² Therefore, high polymer/siRNA weight ratios are reported to be required to fully condense siRNA and enable efficient transfection.¹³ Hyperbranched and branched PBAEs (HPAEs) have a high density of branching linkers, and the resulting three-dimensional globular shape and multiple chain-end groups have the potential of

^aDepartment of Pharmacy, Ludwig-Maximilians-University Munich, Pharmaceutical Technology and Biopharmaceutics, Butenandtstr. 5-13, 81377 Munich, Germany. E-mail: olivia.merkel@lmu.de

^bDepartment of Chemistry and Centre for NanoScience, Ludwig-Maximilians-University Munich, Butenandtstr. 11, 81377 Munich, Germany

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3na00272a>

‡ Present address: Chair of Macromolecular Materials and Fiber Chemistry, Institute of Polymer Chemistry, University of Stuttgart, Pfaffenwaldring 55, 70569 Stuttgart, Germany and University Eye Hospital Tübingen, Center for Ophthalmology, Elfriede-Aulhorn-Straße 7, 72076 Tübingen, Germany.



high siRNA encapsulation efficiency. However, HPAEs with strong nucleic acid binding affinity may restrict the intracellular siRNA release, thus hampering siRNA-mediated gene silencing efficiency.¹² Environment-responsive disulfide linkages containing HPAEs were thus designed and provided promising applications for anti-inflammatory siRNA delivery and for efficient cancer gene therapy in approaches of furthering HPAE efficacy.^{12,14} In this study, brushed PBAEs with spermine side chain were synthesized to overcome some of the limitations reported in the literature.

Spermine is a naturally occurring, biocompatible polycation with primary and secondary amines spaced by methylene groups and has high affinity toward nucleic acids.^{15,16} The essential role of spermine in eukaryotic cells is to aid in packaging cellular DNA into a compact state.^{17,18} However, spermine shows a limited siRNA complexation ability and efficiency for transfecting nucleic acids because of its low molecular weight (~200 Da).¹⁸ In addition, spermines yield limited endosomal escape despite of their good proton-buffering capacity.¹⁹ The polymerization of spermine to increase its molecular weight can improve the products' buffering capacity as well as enhance the endosomal escape and transfection efficiency of spermine polyplexes.^{20,21} In this regard, Lote *et al.* synthesized a variety of oligospermines and found that the molecular weight of the linear oligospermines had a pronounced effect, while the molecular architectures influenced the siRNA encapsulation profiles.¹⁵ Duan *et al.* synthesized a linear polyspermine imidazole-4,5-amide (PSIA), and the resulting PSIA-polyplexes were able to achieve high cellular uptake and efficient luciferase gene silencing.²¹ Jere *et al.* synthesized a hydrophilic poly(β -amino ester) containing spermine and PEG for gene delivery and showed higher transfection efficiency than with PEI (25 kDa).¹⁶ Liu *et al.* synthesized a hyperbranched poly(β -amino ester), in which the end-capping with spermine improved protein binding and thus enhanced cytosolic protein delivery.²²

In this work, we synthesized a spermine-based poly(β -amino ester) combining the advantages of PBAEs with increased numbers of spermine-units in one polymer. We first protected three amines of spermine to facilitate the reaction with one primary amine to form brushed polymers that still contain primary amines. Inspired by our previous research,²³ we found that hydrophobic modification is important for the successful transfection and gene silencing of PBAEs polyplexes. Therefore, decylamine was polymerized together with spermine to give a brush-like poly(β -amino ester) with suitable amphiphilicity.

Results and discussion

In this work, we first converted spermine according to literature procedures to form tri-*tert*-butyl carbonyl spermine, abbreviated as tri-boc-spermine.^{24,25} To obtain a pure product, the crude product was purified by column chromatography. The purity of monomers is important for the following steps during polymer synthesis, and the chemical structure of the tri-boc-spermine was therefore characterized by ¹H NMR spectroscopy (Fig. S1A†).


The tri-boc-spermine and decylamine-based β -amino ester polymer poly(tri-boc-spermine-co-decylamine amino β -amino ester) abbreviated as P(BSpDBAE) was synthesized by the Michael addition-based step-growth polymerization of tri-boc-spermine, decylamine and 1,4-butanediol diacrylate (Scheme 1). As shown in Fig. S1C† the NMR spectrum is in accordance with a polymer consisting of all three monomers, as peaks assigned to all three monomers are visible in the NMR spectrum. The peaks at 1.44 ppm, 1.70 ppm and 3.16 ppm are assigned to tri-boc-spermine; the peaks at 0.88 ppm and 1.26 ppm belong to decylamine; the peaks at 1.70 ppm, 2.46 ppm, 2.82 ppm and 4.11 ppm are assigned to the 1,4-butanediol diacrylate backbone of the polymer. A shift of the peak at 4.18 ppm of 1,4-butanediol diacrylate to 4.11 ppm as well as a decrease in integrals of the acrylate protons indicate the conjugation of the two amine-containing monomers after successful 1,4-Michael-addition. The molar ratio of the two amine monomers was calculated according to the integrations of peaks at 1.70 ppm and 0.88 ppm, and the ratio was approximately 1:1. The reaction was carried out in bulk, as high concentrations of monomers in the absence of solvents can produce PBAEs with higher molecular weights and less intramolecular cyclization while requiring shorter reaction times.^{26,27}

The polymer P(BSpDBAE) was then deprotected by treatment with trifluoro acetic acid (TFA) resulting in poly(spermine-co-decylamine amino β -amino ester) P(SpDBAE). As shown in Fig. S1D† the disappearance of the peak at 1.44 ppm indicates that the *N*-Boc protection groups were removed successfully. The reaction conditions, yield, molecular weight, PDI and protonable unit of the polymers are summarized in Table 1.

Polyplexes between P(SpDBAE) and siRNA were then prepared as described in the ESI† at different N/P ratios. The hydrodynamic diameter (size) and polydispersity index (PDI) of the polyplexes were measured by dynamic light scattering (DLS) and the zeta potential of the polyplexes was determined by laser doppler anemometry (LDA). As shown in Fig. 1A, the size of the polyplexes depended on the N/P ratios with a minimum size of the polyplexes of 37 nm at N/P 7 with a PDI of 0.18. It was hypothesized that the siRNA was not entirely encapsulated at N/P 1 and 3 as the zeta potential was negative, and the observed sizes were comparably large. For the polyplexes at N/P 10 to 20, an excess of free polymer may cause sedimentation, resulting in a comparably high PDI. Size is an important factor for cellular uptake and transfection. Some reports indicate that nanoparticles with a size below 150 nm are required for the uptake in lung cells by endocytosis,²⁸ while other papers report that spermine-based delivery systems with a larger size have a good transfection efficiency *in vivo*.²⁹

To determine the siRNA encapsulation efficiency of P(SpDBAE), SYBR gold assays were performed. SYBR[®] gold stain is a high quantum yield proprietary unsymmetrical cyanine dye which can bind to free nucleic acids and exhibits high fluorescence intensity upon binding.³⁰ As shown in Fig. 2, free siRNA was used as a control and its fluorescence intensity was set as 100%. The amount of free siRNA decreased with the increase of N/P ratio, which reflects siRNA encapsulation by the polymer in polyplexes. Almost all the siRNA was encapsulated from N/P 5





Scheme 1 Synthesis route of P(SpDBAE) (8) by reacting tri-boc spermine (4) with decylamine (5) and 1,4-butanediol diacrylate (6) resulting in P(BSpDBAE) (7) followed by deprotection.

on, which indicates that P(SpDBAE) can encapsulate siRNA efficiently. The SYBR gold results also correspond to the size and zeta potential of the polyplexes. As shown in Fig. 2, the siRNA was not fully encapsulated at N/P 1 and 3, and free siRNA attached to the surface of the polyplexes or remained in solution, thus the zeta potentials of the polyplexes were negative (Fig. 1B). The siRNA can be quantitatively encapsulated from N/P 5 on (Fig. 2), which is corresponding to a positive zeta potential of the formed polyplexes (Fig. 1B).

The morphology of the polyplexes was investigated *via* transmission electron microscopy (TEM) at an FEI TITAN operated at 300 kV. The polyplexes shown in Fig. 3 were mostly spherical. As the white arrows pointed in the figure, particle sizes vary between 20 and 100 nm, which is in accordance with the DLS results (Fig. 1A, N/P 10). Accordingly, the existence of big particles can explain the high PDI of the DLS results.

The cell compatibility of P(SpDBAE) free polymer and P(SpDBAE) polyplexes was measured by MTT assay. MTT (dimethylthiazolyl blue diphenyltetrazolium bromide) is a yellow tetrazole, which can be reduced to purple formazan in living cells.³¹ The method indeed measures the metabolic activity of the cells and reveals the cell viability indirectly. As shown in Fig. 4, the treatment with polymer P(SpDBAE) had a lower effect on the cell viability than hyPEI 25 kDa treatment in general. The IC₅₀ of P(SpDBAE) was $43.5 \mu\text{g mL}^{-1}$ and the IC₅₀ of PEI was calculated as $10.5 \mu\text{g mL}^{-1}$ (Fig. S2†). The cell viability of P(SpDBAE) polyplexes at N/P 5, 7 and 10 was 79.8%, 75.9% and 64.7% respectively. The cell viability of P(SpDBAE) polyplexes decreased from N/P 5 to 10 because of the increasing amount of excess free polymer. Interestingly, the viability of

cells transfected with PEI polyplexes was better than compared with P(SpDBAE) polyplexes. This observation was attributed to the smaller protonable unit of PEI than that of P(SpDBAE),




Fig. 1 (A) Hydrodynamic diameter (size) and polydispersity index (PDI) of P(SpDBAE) polyplexes and (B) zeta potential of P(SpDBAE) polyplexes at various N/P ratios (mean \pm SD, $n = 3$).

Table 1 Step-growth polymerization (polyaddition) of tri-boc spermine, decylamine and 1,4-butanediol diacrylate

Polymer	Solvent	Time (h)	Yield (%)	M_n (Da)	D	Protonable unit
P(BSpDBAE) ^a	—	15	44	6000 ^c	1.83 ^c	—
P(SpDBAE) ^b	DCM	2	62	6200 ^d	—	220

^a Reaction conditions: no solvent, 120°C , overnight. ^b Reaction conditions: 100 mg polymer, 1 mL TFA, 20 mL dichloromethane, room temperature, 2 h. ^c M_n and D were tested *via* SEC (measurement relative to polystyrene and in chloroform at 40°C). ^d Molecular weight was calculated on the basis of the M_n of P(BSpDBAE) and the theoretical chemical structure of P(SpDBAE) as TFA salt.






Fig. 2 siRNA encapsulation profiles of P(SpDBAE) polyplexes measured by SYBR gold assays at various N/P ratios. 100% values (N/P = 0) are represented by the determined fluorescence of uncondensed free siRNA (data points indicate mean \pm SD, $n = 3$).




Fig. 3 TEM images of P(SpDBAE) polyplexes at N/P 10.

resulting in smaller weight amounts of PEI necessary for preparing the polyplexes than the weight amount of P(SpDBAE) in P(SpDBAE) polyplexes. Besides, the cellular uptake of P(SpDBAE) polyplexes was much higher than that of PEI polyplexes (Fig. 5), which could also lead to stronger cytotoxicity. Although the cell compatibility of P(SpDBAE) polyplexes seems not as good as the compatibility of PEI polyplexes, the PBAE is biodegradable. PBAE degradation products are considered to be benign to mammalian cells and were reported to have limited influence on the metabolic activity of healthy cells.³² When applied *in vivo*, several doses of polyplexes may be required to obtain a therapeutic effect and for improved long-term efficacy.³³ Although no animal studies were performed in this initial set of experiments, the characteristics observed here seem favorable for an *in vivo* follow-up experiment.

The cellular uptake of P(SpDBAE) polyplexes was quantified by flow cytometry and compared to hyperbranched polyethylenimine (hyPEI, 25 kDa) polyplexes as a positive control and free AF488-siRNA as a negative control. Extracellular fluorescence associated with non-internalized polyplexes on the cell surface was quenched with 0.4% trypan blue.




Fig. 4 Cell viability of P(SpDBAE) and P(SpDBAE) polyplexes determined by dimethylthiazolyl blue diphenyltetrazolium bromide (MTT) assay in H1299 cells (mean \pm SD, $n = 3$, two-way ANOVA with Bonferroni multiple comparison test, ns: $p > 0.05$, *: $p < 0.5$).

As shown in Fig. 5, the median fluorescence intensities of all the formulations showed no significant difference before and after quenching with trypan blue, which confirms that the determined fluorescence stems from the polyplexes that were internalized into the cells. The uptake of P(SpDBAE) polyplexes at N/P 5 was 59 times higher than that of free AF488-siRNA (negative control) and 3 times higher than that of hyPEI25K polyplexes (positive control); the uptake of P(SpDBAE) polyplexes at N/P 7 was 87 times higher than the negative and 5 times higher than the positive control; the uptake of P(SpDBAE) polyplexes at N/P 10 was 133 times higher than negative and 12 times higher than positive control. The cellular uptake of




Fig. 5 Cellular uptake of P(SpDBAE) polyplexes quantified by flow cytometry and presented as median fluorescence intensity corrected for autofluorescence of untreated blank cells (H1299 cells, AF488-siRNA, mean \pm SD, $n = 3$, statistics of the quenched group, one-way ANOVA with Bonferroni multiple comparison test, ***: $p < 0.001$, ns: $p > 0.05$).



P(SpDBAE) polyplexes increased from N/P 5 to 10, while the uptake of hyPEI25K polyplexes decreased from N/P 5 to 10.

The cellular uptake of the polyplexes was determined from N/P 5 on, where the siRNA is quantitatively encapsulated according to the SYBR gold assays (Fig. 2). The highest N/P ratio chosen in this experiment was N/P 10 to avoid any possible cytotoxicity at higher concentrations of free polymer. The cellular uptake of P(SpDBAE) polyplexes was in general higher than the PEI polyplexes, which could be favored by the interaction of the hydrophobic C10 chains of decylamine with cell membranes. Hydrophobic modifications have successfully improved the transfection efficiency in the past.³⁴ Interestingly, the cellular uptake of P(SpDBAE) polyplexes increased as the N/P ratio increased from N/P 5 to 10, regardless of the PDI of the polyplexes; while for PEI polyplexes, the cellular uptake decreased from N/P 5 to 10, which may not be attributed to potential cytotoxicity of PEI according to the MTT assay but could indicate that the size of the PEI polyplexes was too disperse at high N/P ratios (Fig. S3†).

To determine the gene silencing efficiency of P(SpDBAE) polyplexes on the protein level, GFP knockdown assays were performed using enhanced green fluorescence protein expressing cells (H1299-eGFP) to quantify the median fluorescence intensity *via* flow cytometry. Lipofectamine™ 2000 (LF) was used as positive control and LF and P(SpDBAE) were used to encapsulate scrambled siRNA (siNC) as negative control. As shown in Fig. 6, the knockdown efficiency of P(SpDBAE) polyplexes at N/P 5, 7 and 10 was 89.7%, 90.3% and 94.3% respectively. Accordingly, higher cellular uptake of P(SpDBAE) polyplexes led to higher levels of GFP knockdown.

In fact, the cellular uptake and knockdown does not always show a positive correlation. For example, Dosta *et al.* synthesized a group of PBAEs. Although the cholesterol-modified polymers showed lower siRNA uptake than the unmodified hexylamine and hexadecylamine pendant polymers, the GFP knockdown efficiency of cholesterol-modified polymers was still comparable with the unmodified PBAEs.³⁵




Fig. 6 Enhanced green fluorescent protein (eGFP) knockdown of P(SpDBAE) polyplexes in H1299 cells expressing eGFP quantified by flow cytometry as median fluorescence intensity, LF: Lipofectamine™ 2000 (mean \pm SD, $n = 3$, one-way ANOVA with Bonferroni multiple comparison test, *** $p < 0.001$).

In our case, higher cellular uptake led to more efficient gene silencing efficiency. As far as we understand, the correlation between cellular uptake and gene knockdown mainly depends on the endosomal escape ability of the polyplexes.⁸ If the polyplexes can escape from the endosomes and lysosomes successfully, high cellular uptake commonly results in efficient gene silencing. However, if the polyplexes have poor ability to escape from endosomes or lysosomes, most of the polyplexes will be entrapped in the latter compartment, and the siRNA will be degraded eventually. In that case, high cellular uptake does not correlate with efficient gene silencing. In addition, the polyplexes should not be too cytotoxic in order to silence gene expression successfully without off-target effects.³⁶ For the same polyplexes with different N/P ratios, the formulations with high cellular uptake usually results in high gene silencing efficiency. However, when comparing polyplexes with and without modification, the modified polyplexes may have low cellular uptake but high gene silencing efficiency.³⁵ Kwon *et al.* modified PEI with a membrane-lytic peptide called HGP taken from the endodomain of HIV gp41. The PEI-HGP polyplexes showed slightly lower cellular uptake than PEI but the transfection efficiency of PEI-HGP polyplexes was significantly higher than that of unmodified PEI. This effect was explained by the enhanced endosomal escape mediated by the HGP peptide.³⁷

The gene silencing efficacy of polyplexes also strongly depends on the polymers. After the first use of PBAEs for gene delivery by Langer's group,¹¹ a lot of PBAEs were synthesized and researchers tried to understand the relationship between the properties and the chemical structures of PBAEs.^{38,39} It was found that amine-terminated PBAEs are more suitable for gene delivery, and the transfection potential of PBAEs can also be effected by molecular weight.⁴⁰ For example, PBAEs with molecular weight less than 11 kDa were unable to form stable polyplexes even at a high 150 : 1 polymer to DNA weight ratio, however, PBAEs at molecular weight more than 13 kDa ($M_w = 13\ 100$ and $13\ 400$) were able to stably complex DNA even at polymer to DNA weight ratio as low as 10 : 1, and showed the highest luciferase expression.⁴⁰ In addition, low molecular weight PBAEs ($M_w < 8$ kDa) only poorly transfect DNA compared with higher molecular weight versions, which is the same trend as observed for PEI.³⁹⁻⁴¹ However, we found that for siRNA formulation and delivery investigated here, the molecular weight of PBAEs does not necessarily need to be higher than 8 kDa. Instead, a suitable amphiphilicity may be the determining factor.³⁵

P(SpDBAE) polyplexes mediated efficient gene silencing at N/P 5 (polymer/siRNA weight ratio 3.5). Compared with polyplexes prepared from cross-linked PEI 800, which achieved gene silencing efficiency of 46% at N/P 115.05,⁴² and another PBAE polyplexes with 92% GFP knockdown at polymer/siRNA weight ratio 445,⁴³ the N/P ratio of our polyplexes is rather low, and gene silencing is highly efficient. Low N/P ratios are expected to cause less cytotoxicity or side effects when applied *in vivo*. In the case of intravenous administration, polyplexes encounter a complex environment with subsequent interaction with hundreds of serum proteins. Negatively charged proteins may attach to the polyplexes and form the so-called "protein



corona”, which can alter the endocytic pathway of the polyplexes and lower the transfection efficiency due to the reduced endo/lysosomal escape.^{44,45} P(SpDBAE) polyplexes can be effectively applied in complete cell culture medium regardless of the presence of proteins in serum. Although the serum concentration in cell culture is lower than the serum concentration in full blood, our results still indicate the potential application of the polyplexes *in vivo*.

Conclusions

Safe and efficient transfection of siRNA has remained a challenge for many years. In this study, we successfully synthesized a novel poly(β -amino ester) composed of decylamine, spermine and 1,4-butanediol diacrylate. The free polymer has higher biocompatibility than the commonly used cationic polymer PEI, and its polyplexes achieved a high cellular uptake and around 90% GFP knockdown at low N/P ratios in complete cell culture medium. These results suggest that this new PBAE P(SpDBAE) is very promising for siRNA delivery and it could be one of the most efficient PBAEs for siRNA delivery reported so far.

Author contributions

Conceptualization, Yao Jin, Friederike Adams, and Olivia M. Merkel; methodology and investigation, Yao Jin and Friederike Adams; TEM characterisation, Sebastian Sturm and Müller-Caspary; original manuscript preparation, Yao Jin; review and editing, Friederike Adams and Olivia M. Merkel; funding acquisition, Olivia M. Merkel.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Yao Jin appreciates the financial support from China Scholarship Council (CSC201906010329). This project was funded by ERC-2014-StG – 637830 to Olivia Merkel.

References

- 1 J. Valencia-Serna, C. Kucharski, M. Chen, R. Kc, X. Jiang, J. Brandwein and H. Uludag, *J. Controlled Release*, 2019, **310**, 141–154.
- 2 A. Mehta, E. Dalle Vedove, L. Isert and O. M. Merkel, *Pharm. Res.*, 2019, **36**, 133.
- 3 M. Z. Wang, J. Niu, H. J. Ma, H. A. Dad, H. T. Shao, T. J. Yuan and L. H. Peng, *J. Controlled Release*, 2020, **322**, 95–107.
- 4 H. Uludağ, K. Parent, H. M. Aliabadi and A. Haddadi, *Front. Bioeng. Biotechnol.*, 2020, **8**, 916.
- 5 A. Mehta, T. Michler and O. M. Merkel, *Adv. Healthcare Mater.*, 2021, **10**, e2001650.
- 6 C. M. O'Driscoll, A. Bernkop-Schnürch, J. D. Friedl, V. Prétat and V. Jannin, *Eur. J. Pharm. Sci.*, 2019, **133**, 190–204.
- 7 M. I. Sajid, M. Moazzam, S. Kato, K. Yeseom Cho and R. K. Tiwari, *Pharmaceuticals*, 2020, **13**, 294.
- 8 M. Dominska and D. M. Dykxhoorn, *J. Cell Sci.*, 2010, **123**, 1183–1189.
- 9 G. Cavallaro, C. Sardo, E. F. Craparo, B. Porsio and G. Giammona, *Int. J. Pharm.*, 2017, **525**, 313–333.
- 10 J. J. Green, R. Langer and D. G. Anderson, *Acc. Chem. Res.*, 2008, **41**, 749–759.
- 11 D. M. Lynn and R. Langer, *J. Am. Chem. Soc.*, 2000, **122**, 10761–10768.
- 12 X. Wang, Q. Liang, Y. Mao, R. Zhang, Q. Deng, Y. Chen, R. Zhu, S. Duan and L. Yin, *Biomater. Sci.*, 2020, **8**, 3856–3870.
- 13 K. L. Kozielski, S. Y. Tzeng, B. A. Hurtado De Mendoza and J. J. Green, *ACS Nano*, 2014, **8**, 3232–3241.
- 14 S. Liu, Y. Gao, A. Sigen, D. Zhou, U. Greiser, T. Guo, R. Guo and W. Wang, *ACS Biomater. Sci. Eng.*, 2016, **3**, 1283–1286.
- 15 A. R. Lote, V. R. Kolhatkar, T. Insley, P. Král and R. Kolhatkar, *ACS Macro Lett.*, 2014, **3**, 829–833.
- 16 D. Jere, T. H. Kim, R. B. Arote, H. L. Jiang, M. H. Cho, J. W. Nah and C. S. Cho, *Pharm. Res.*, 2007, **25**, 875–885.
- 17 H. Eliyahu, S. Siani, T. Azzam, A. J. Domb and Y. Barenholz, *Biomaterials*, 2006, **27**, 1646–1655.
- 18 M. Elsayed, V. Corrand, V. Kolhatkar, Y. Xie, N. H. Kim, R. Kolhatkar and O. M. Merkel, *Biomacromolecules*, 2014, **15**, 1299–1310.
- 19 J. G. Hardy, M. A. Kostianen, D. K. Smith, N. P. Gabrielson and D. W. Pack, *Bioconjugate Chem.*, 2006, **17**, 172–178.
- 20 M. S. Shim and Y. J. Kwon, *Biomaterials*, 2011, **32**, 4009–4020.
- 21 S.-Y. Duan, X.-M. Ge, N. Lu, F. Wu, W. Yuan and T. Jin, *Int. J. Nanomed.*, 2012, **7**, 3813.
- 22 X. Liu, Z. Zhao, F. Wu, Y. Chen and L. Yin, *Adv. Mater.*, 2022, **34**, 2108116.
- 23 V. Nadithe, R. Liu, B. A. Killinger, S. Movassaghian, N. H. Kim, A. B. Moszczynska, K. S. Masters, S. H. Gellman and O. M. Merkel, *Mol. Pharmaceutics*, 2015, **12**, 362–374.
- 24 I. S. Blagbrough and A. J. Geall, *Tetrahedron Lett.*, 1998, **39**, 439–442.
- 25 S. K. M. Nalluri, J. Voskuhl, J. B. Bultema, E. J. Boekema and B. J. Ravoo, *Angew. Chem., Int. Ed.*, 2011, **50**, 9747–9751.
- 26 A. Akinc, D. M. Lynn, D. G. Anderson and R. Langer, *J. Am. Chem. Soc.*, 2003, **125**, 5316–5323.
- 27 J. Chen, S.-W. Huang, M. Liu and R.-X. Zhuo, *Polymer*, 2007, **48**, 675–681.
- 28 T. Leubhardt, S. Roesler, M. Beck-Broichsitter and T. Kissel, *J. Drug Delivery Sci. Technol.*, 2010, **20**, 171–180.
- 29 H.-L. Jiang, S.-H. Hong, Y.-K. Kim, M. A. Islam, H.-J. Kim, Y.-J. Choi, J.-W. Nah, K.-H. Lee, K.-W. Han and C. Chae, *Int. J. Pharm.*, 2011, **420**, 256–265.
- 30 R. S. Tuma, M. P. Beaudet, X. Jin, L. J. Jones, C.-Y. Cheung, S. Yue and V. L. Singer, *Anal. Biochem.*, 1999, **268**, 278–288.
- 31 T. Mosmann, *J. Immunol. Methods*, 1983, **65**, 55–63.
- 32 Y. Liu, Y. Li, D. Keskin and L. Shi, *Adv. Healthcare Mater.*, 2019, **8**, e1801359.
- 33 S. J. Gwak, C. Macks, D. U. Jeong, M. Kindy, M. Lynn, K. Webb and J. S. Lee, *Biomaterials*, 2017, **121**, 155–166.



- 34 M. Zheng, Y. Zhong, F. Meng, R. Peng and Z. Zhong, *Mol. Pharmaceutics*, 2011, **8**, 2434–2443.
- 35 P. Dosta, V. Ramos and S. Borrós, *Mol. Syst. Des. Eng.*, 2018, **3**, 677–689.
- 36 L. Parhamifar, A. K. Larsen, A. C. Hunter, T. L. Andresen and S. M. Moghimi, *Soft Matter*, 2010, **6**, 4001–4009.
- 37 E. J. Kwon, J. M. Bergen and S. H. Pun, *Bioconjugate Chem.*, 2008, **19**, 920–927.
- 38 D. G. Anderson, D. M. Lynn and R. Langer, *Angew. Chem., Int. Ed.*, 2003, **42**, 3153–3158.
- 39 D. G. Anderson, A. Akinc, N. Hossain and R. Langer, *Mol. Ther.*, 2005, **11**, 426–434.
- 40 A. Akinc, D. G. Anderson, D. M. Lynn and R. Langer, *Bioconjugate Chem.*, 2003, **14**, 979–988.
- 41 S. Choosakoonkriang, B. A. Lobo, G. S. Koe, J. G. Koe and C. R. Middaugh, *J. Pharmaceut. Sci.*, 2003, **92**, 1710–1722.
- 42 X. Ge, J. Feng, S. Chen, C. Zhang, Y. Ouyang, Z. Liu and W. Yuan, *J. Nanobiotechnol.*, 2014, **12**, 1–8.
- 43 K. L. Kozielski, S. Y. Tzeng and J. J. Green, *Chem. Commun.*, 2013, **49**, 5319–5321.
- 44 K. E. Wheeler, A. J. Chetwynd, K. M. Fahy, B. S. Hong, J. A. Tochihiuti, L. A. Foster and I. Lynch, *Nat. Nanotechnol.*, 2021, **16**, 617–629.
- 45 D. Zhu, H. Yan, Z. Zhou, J. Tang, X. Liu, R. Hartmann, W. J. Parak, N. Feliu and Y. Shen, *Biomater. Sci.*, 2018, **6**, 1800–1817.

